Affordable Access

deepdyve-link
Publisher Website

Failure rates and survival times of systemic and biologic therapies in treating psoriasis: a retrospective study.

Authors
  • Sutaria, Nishadh1
  • Au, Shiu-Chung1, 2
  • 1 Tufts University School of Medicine, Boston, MA, USA.
  • 2 Department of Dermatology, Tufts Medical Center, Boston, MA, USA.
Type
Published Article
Journal
Journal of Dermatological Treatment
Publisher
Informa UK (Taylor & Francis)
Publication Date
Sep 01, 2021
Volume
32
Issue
6
Pages
617–620
Identifiers
DOI: 10.1080/09546634.2019.1688756
PMID: 31682477
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Systemic and biologic therapies have varying failure rates and survival times in treating psoriasis. We aim to describe the patterns of therapy failure in psoriasis patients. A retrospective (January 2009 to May 2018) analysis of 250 psoriasis patients seen at a psoriasis referral center, and 806 treatment courses of several systemic and biologic therapies, was conducted to determine failure rates and survival times for systemic and biologic therapies. Systemic therapies failed more often due to their adverse effects (16.4% vs 7.2%, p < .001). Biologics failed more often due to secondary failure (24.2% vs. 9.3%, p < .001). Biologics had a longer survival time (23.9 ± 22.2 vs. 12.6 ± 15.4 months, p < .001), even with early failures (≤6 months) removed (29.0 ± 22.5 vs. 21.1 ± 16.4 months, p = .014). Tertiary referral center, unreported causes of failure, sample size. Systemic therapies fail more often due to adverse effects while biologics fail more often due to loss of efficacy. Biologic therapies have longer survival times than systemic therapies.

Report this publication

Statistics

Seen <100 times